Targeted therapy in renal cell carcinoma: moving from molecular agents to specific immunotherapy

Area of Science:

• Oncology
• Immunology
• Cancer Therapy

Background:

• Metastatic renal cell carcinoma (mRCC) treatment historically relied on non-specific immunotherapy.
• Specific targeted molecular therapies, including VEGF and mTOR inhibitors, have largely replaced older immunotherapies.
• Current immunotherapy approaches require further development for enhanced accuracy in mRCC treatment.

Purpose of the Study:

• To review recent advancements in immunotherapy strategies for metastatic renal cell carcinoma.
• To highlight the potential of specific immunotherapy approaches, particularly peptide vaccination.
• To discuss combinatory strategies and immune checkpoint modulators in mRCC immunotherapy.

Main Methods:

• Review of current literature on immunotherapy for mRCC.
• Focus on peptide vaccination strategies targeting tumor-specific T lymphocytes.
• Discussion of combination therapies with immunomodulating agents (e.g., cyclophosphamide, sunitinib).
• Analysis of immune checkpoint modulators, including anti-CTLA-4 and PD-1 antibodies.

Main Results:

• Immunotherapy is re-emerging in clinical studies due to advancements towards targeted approaches.
• Peptide vaccination shows promise for specific tumor targeting via T lymphocytes.
• Combinations with agents like cyclophosphamide and sunitinib are being explored.
• Immune checkpoint modulators (anti-CTLA-4, PD-1) are key areas of investigation.

Conclusions:

• The evolution towards specific immunotherapy, including peptide vaccination, is revitalizing treatment options for mRCC.
• Combinatorial strategies and immune checkpoint inhibition represent promising avenues for improving mRCC immunotherapy.
• Further research is needed to optimize these targeted immunotherapies for better patient outcomes.